Endocrinology Service, Memorial Sloan Kettering Cancer Center, New York, New York
J Nucl Med. 2018 Aug;59(8):1187-1194. doi: 10.2967/jnumed.117.192559. Epub 2018 Apr 13.
The lack of prospective randomized clinical trials for most management topics in differentiated thyroid cancer forces us to make management recommendations based on retrospective observational data, which are often incomplete, subject to selection bias, and conflicting. Therefore, it is not surprising that many aspects of thyroid cancer management remain controversial and not well defined. This review will examine the controversies surrounding 3 important topics in thyroid cancer management: the option of thyroid lobectomy as initial therapy, the use of preoperative neck imaging to optimize the completeness of the initial surgery, and the selective use of radioactive iodine for remnant ablation, adjuvant treatment, or treatment for known persistent or recurrent disease. As thyroid cancer management moves toward a much more risk-adapted approach to personalized recommendations, clinicians and patients must balance the risks and benefits of the potential options to arrive at a plan that is optimized regarding both patient preferences/values and the philosophy/experience of the local disease management team.
由于大多数分化型甲状腺癌的管理主题缺乏前瞻性随机临床试验,我们不得不根据回顾性观察数据提出管理建议,而这些数据往往是不完整的,容易受到选择偏倚的影响,并且相互矛盾。因此,甲状腺癌管理的许多方面仍然存在争议且尚未得到明确界定也就不足为奇了。本综述将探讨甲状腺癌管理中 3 个重要主题的争议:甲状腺叶切除术作为初始治疗的选择、术前颈部影像学检查以优化初始手术的完整性,以及放射性碘在残余消融、辅助治疗或治疗已知持续性或复发性疾病中的选择性使用。随着甲状腺癌管理朝着更具风险适应性的个体化建议方法发展,临床医生和患者必须权衡潜在选择的风险和益处,以制定一个既考虑到患者的偏好/价值观,又考虑到当地疾病管理团队的理念/经验的最佳计划。